Postdoctoral fellow
+420 495 833 195
ondrej.benek@fnhk.cz
ORCID: 0000-0001-6840-1933
Ondrej obtained his MSc in 2011 at the Faculty of Pharmacy, Charles University. The main aim of his diploma thesis was to synthesize quaternary compounds as potential inhibitors of acetylcholinesterase. In 2016 he successfully finished his postgraduate studies at the Faculty of Military Health Sciences, University of Defence and obtained the doctoral degree from Toxicology. Within the topic of his dissertation thesis he concerned himself with design, synthesis and evaluation of modulators of mitochondrial enzymes as potential therapeutics of Alzheimer's disease.
He is currently working as postdoc/ academic fellow at the Faculty of Science, University of Hradec Kralove and as a researcher at the Biomedical Research Center, University Hospital in Hradec Kralove and National Institute of Mental Health, Klecany.
| PharmDr. | (2017) | Medicinal chemistry, Faculty of Pharmacy, Charles University |
| Ph.D. | (2016) |
Toxicology, Faculty of Military Health Sciences, University of Defence |
| Mgr. | (2011) |
Pharmacy, Faculty of Pharmacy, Charles University |
Design, synthesis and evaluation of novel therapeutics
Alzheimer's disease
| Since 2016 | postdoc/academic fellow, University of Hradec Kralove, Faculty of Science, CZ |
| Since 2015 | researcher, National Institute of Mental Health, CZ |
| Since 2012 | researcher, University Hospital in Hradec Kralove, Biomedical Research Center, CZ |
| 2017 |
Faculty of Pharmacy, University of Ljubljana, Slovenia (3 months) |
| 2014 | Institute of General Organic Chemistry, CSIC, Madrid, Spain (2 months) |
| 2013 | Biomedical Sciences Research Centre, University of St Andrews, UK (1 month) |
| Title: | Výzkum oxim-CB(7) komplexů při prostupu kvarterních reaktivátorů acetylcholinestarasy do centrálního nervového systému |
| Funding: |
Grantová agentura ČR (18-08937S) |
| Schedule: | 2018–2020 |
| Role: | member of a team |
| Title: |
Reaktivátor acetylcholinesterasy s potenciálně aktivním transportem přes hematoencefalickou bariéru |
| Funding: |
Interní grantová soutěž FN HK |
| Schedule: | 2018 |
| Role: | principal investigator |
| Title | Modulátory mitochondriálních enzymů k léčbě neurodegenerativních onemocnění |
| Funding: | Agentura pro zdravotnický výzkum ČR (NV15-28967A) |
| Schedule: | 2015–2018 |
| Role: | Member of a team |
| Title | Příprava a testování léčiv s potenciálním profylaktickým efektem proti nervově paralytickým látkám a Alzheimerově nemoci |
| Funding: | Ministerstvo školství, mládeže a tělovýchovy (No. SV/FVZ201201) |
| Schedule: | 2012–2014 |
| Role: | member of a team |
| Since 2011 | Medical and Biological Sciences Building, School of Biology, University of St. Andrews, Scotland |
| Since 2016 |
Teaching of subjects Toxicology of inorganic and organic compounds; General and inorganic chemistry; Laboratory practice in bioorganic chemistry at Faculty of Science UHK |
Author or co-author of 10 scientific publications with IF
H-index: 4
Citations without autocitations: 36
(dated 6/2018)
Benek, O.; Hroch, L.; Aitken, L.; Gunn-Moore, F.; Vinklarova, L.; Kuca, K.; Perez, D. I.; Perez, C.; Martinez, A.; Fisar, Z.; Musilek, K. 1-(Benzo[d]thiazol-2-yl)-3-Phenylureas as Dual Inhibitors of Casein Kinase 1 and ABAD Enzymes for Treatment of Neurodegenerative Disorders. J. Enzyme Inhib. Med. Chem. 2018, 33 (1), 665–670. DOI: 10.1080/14756366.2018.1445736. IF = 4.293
Honegr, J.; Malinak, D.; Dolezal, R.; Soukup, O.; Benkova, M.; Hroch, L.; Benek, O.; Janockova, J.; Kuca, K.; Prymula, R. Rational Design of Novel TLR4 Ligands by in Silico Screening and Their Functional and Structural Characterization in Vitro. Eur. J. Med. Chem. 2018, 146, 38–46. DOI: 10.1016/j.ejmech.2017.12.074. IF = 4.519
Benek, O.; Hroch, L.; Aitken, L.; Dolezal, R.; Hughes, R.; Guest, P.; Benkova, M.; Soukup, O.; Musil, K.; Kuca, K.; Smith, T. K.; Gunn-Moore, F.; Musilek, K. 6-Benzothiazolyl Ureas, Thioureas and Guanidines Are Potent Inhibitors of ABAD/17 Beta-HSD10 and Potential Drugs for Alzheimer’s Disease Treatment: Design, Synthesis and in Vitro Evaluation. Med. Chem. 2017, 13 (4), 345–358, DOI: 10.2174/1573406413666170109142725. IF = 2.331
Hroch, L.; Guest, P.; Benek, O.; Soukup, O.; Janockova, J.; Dolezal, R.; Kuca, K.; Aitken, L.; Smith, T. K.; Gunn-Moore, F.; Zala, D.; Ramsay, R. R.; Musilek, K. Synthesis and Evaluation of Frentizole-Based Indolyl Thiourea Analogues as MAO/ABAD Inhibitors for Alzheimer’s Disease Treatment. Bioorg. Med. Chem. 2017, 25 (3), 1143–1152, DOI: 10.1016/j.bmc.2016.12.029. IF = 2.930
Hroch, L.; Benek, O.; Guest, P.; Aitken, L.; Soukup, O.; Janockova, J.; Musil, K.; Dohnal, V.; Dolezal, R.; Kuca, K.; Smith, T. K.; Gunn-Moore, F.; Musilek, K. Design, Synthesis and in Vitro Evaluation of Benzothiazole-Based Ureas as Potential ABAD/17β-HSD10 Modulators for Alzheimer’s Disease Treatment. Bioorg. Med. Chem. Lett. 2016, 26, 3675–3678, DOI: 10.1016/j.bmcl.2016.05.087. IF = 2.420
Andrs, M.; Muthna, D.; Rezacova, M.; Seifrtova, M.; Siman, P.; Korabecny, J.; Benek, O.; Dolezal, R.; Soukup, O.; Jun, D.; Kuca, K. Novel Caffeine Derivatives with Antiproliferative Activity. RSC Adv. 2016, 6 (39), 32534–32539, DOI:10.1039/C5RA22889A. IF = 3.84
Benek, O.; Soukup, O.; Pasdiorova, M.; Hroch, L.; Sepsova, V.; Jost, P.; Hrabinova, M.; Jun, D.; Kuca, K.; Zala, D.; Ramsay, R. R.; Marco-Contelles, J.; Musilek, K. Design, Synthesis and in Vitro Evaluation of Indolotacrine Analogues as Multitarget-Directed Ligands for the Treatment of Alzheimer’s Disease. ChemMedChem. 2016, 11, 1264–1269, DOI: 10.1002/cmdc.201500383. IF = 2.968
Benek, O.; Aitken, L.; Hroch, L.; Kuca, K.; Gunn-Moore, F.; Musilek, K. A Direct Interaction between Mitochondrial Proteins and Amyloid-Β Peptide and Its Significance for the Progression and Treatment of Alzheimer’s Disease. Curr. Med. Chem. 2015, 22, 1056–1085, DOI: 10.2174/0929867322666150114163051. IF = 3.853
Hroch, L.; Aitken, L.; Benek, O.; Dolezal, M.; Kuca, K.; Gunn-Moore, F.; Musilek, K. Benzothiazoles - Scaffold of Interest for CNS Targeted Drugs. Curr. Med. Chem. 2015, 22, 730–747, DOI: 10.2174/0929867322666141212120631. IF = 3.853
Benek, O.; Musilek, K.; Horova, A.; Dohnal, V.; Dolezal, R.; Kuca, K. Preparation, In Vitro Screening and Molecular Modelling of Monoquaternary Compounds Related to the Selective Acetylcholinesterase Inhibitor BW284c51. Med. Chem. 2014, 11, 21–29, DOI: 10.2174/1573406410666140428153110. IF = 1.387
